U-Ploid Biotechnologies published a paper evaluating outcomes in transferring aneuploid embryos in Fertility & Sterility.

U-Ploid is a biotechnology company developing first-in-class reproductive health therapeutics to address the global unmet need of age-related fertility decline. The Company’s lead program is a first-in-class drug candidate, with promising preclinical activity against age-related damage in oocytes. Co-founded by leading scientists and industry experts, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. U-Ploid is committed to improving access to better reproductive health outcomes and envisions a future where anyone who wants to start a family, can.